Curious if your clinical research has real-world business potential? Join our panel discussion in unpacking how to navigate risk assessment and make confident, informed decisions about turning academic science into a viable commercial venture.

Join our panelists; Barbara Diehl (SPRIND), Peter Mumford (Potter Clarkson LLP) and Julia Wagner (Positron Ventures), by clicking here.

Barbara is a proven expert in entrepreneurship, innovation and education. In Oxford, she led early-stage investment programs and an executive education program for fast-growing small businesses. Following her return to Germany, she served as Director of Transfer and Innovation at the Helmholtz Association of German Research Centres, and now works at SPRIN-D, the German Federal Agency for Breakthrough Innovation.

Peter is a UK and European patent attorney specialising in chemical inventions, particularly small molecule therapeutics, pharmaceutical formulations, and new medical uses.  He works with a broad range of clients, with considerable experience of helping spin-off and start-up life science companies to prepare for fundraising as well as due diligence for investors.

Julia is an investor at Positron Ventures, focusing on early-stage deep tech start-ups across Europe. She is passionate about turning breakthrough science into scalable companies, holds a PhD from ETH Zurich, and previously built a student-led venture fund investing in university spin-offs.

Questions will be encouraged during this talk.

This showcase is sponsored through Aston University’s active involvement with the West Midlands Health Tech Innovation Accelerator (WMTHIA). The WMHTIA is funded by the Department for Science, Innovation and Technology, in partnership with the West Midlands Combined Authority and Innovate UK.